Posts

As early as 2023, pharmaceutical manufacturers and payers will have to contend with one of the more imminent potential impacts of the law: inflationary rebates for Medicare utilization.

For emerging manufacturers, listing through all the steps of a launch plan can be intimidating, so hearing that medical affairs and communications needs to be integrated from the beginning can feel like one more thing is being added to the overflowing to-do list of an understaffed team.

Clarify Health, a leading cloud analytics and value-based payments platform company, and Datavant, the leader in helping organizations securely connect health data, today announced an expanded collaboration to enable life sciences companies to connect their proprietary, first-party data in Clarify’s AI-powered Atlas analytics platform to improve clinical development and commercial operations.

There has been an emphasis on the use of real-world data and real-world evidence in crafting messages for payers. But experts say the insights generated by RWD and RWE are extremely useful in understanding clinicians and patients.

While 90 may not be the new 40, it may become the new 75 or 80 as science, technology and policies converge to leverage the gains from the genomics revolution, which are making precision medicine a clinical reality.

As clinical stage biotech and pharmaceutical firms face unprecedented challenges in raising capital to fund their clinical trial program, strategic trade-offs are coming fast and furious. One of those at the top of the list is when and how to build a commercialization strategy, including navigating the complex work of securing market access.

Even with the COVID-19 emergency measures, payers still had an eye on the potential flood of gene therapies for rare diseases brewing in the pipeline, and were pondering new ways to pay for them. 

Lumanity today announced the acquisition of Endpoint Outcomes, a company specializing in harnessing the voice of patients to document the impact of treatments on health-related quality of life. Lumanity CEO Jon Williams says, “We look forward to working with our new colleagues to define and build market-leading, patient-centered research services to address both HTA and payer needs, and we are confident that our work will yield innovative new solutions for our clients and partners.”

EVERSANA, a pioneer of next-generation commercial services to the global life sciences industry, today unveiled EVERSANA INTOUCH, marking the transformation of its full-service, global healthcare agency network serving the life sciences industry. Combining the power of world-class creative, media and digital innovation with payer, patient, and healthcare communications expertise, EVERSANA INTOUCH reinvents life sciences marketing as the first and only agency accelerating brand performance through insights and seamless connectivity to EVERSANA’s integrated commercialization solutions.